AP-01 / Apmonia Therap - LARVOL DELTA

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research. (PubMed, Mol Cancer) - "Our study thus (1) proposes a CD47-based stratification of patients who may be most likely to benefit from postoperative immunotherapy, and (2) suggests that TAX2 is a potential alternative therapy for patients relapsing on PARP inhibitors."

Biomarker • IO biomarker • Journal • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • CD47 • CD8

Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi). (ASCO 2024) - P2 | "To assess the efficacy of TAX2 and/or PARPi (olaparib) treatment, we used ID8 cells harboring Trp53 -/- and Brca2 -/- mutations, as a pertinent syngeneic representation of intraperitoneal high-grade serous TP53 and BRCA2 mutated OC. Our findings propose TAX2 as a promising strategy for patients relapsing on PARP inhibitors. TAX2 displayed a selective biodistribution pattern in mice, concentrating at tumor sites. Our study showcased that while TAX2 alone exhibited significant but modest activity in PARPi-naive mice, its efficacy significantly increased post-PARPi exposure, irrespective of PARPi duration."

Clinical • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA2 • SIRPA